StockData
AstraZeneca PLC logo

AstraZeneca PLC (AZN) stock

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $14.23B, up 4.8% from the year before. Over ten years it grew 9.0% a year on average. The highest annual figure on record is $14.23B in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.23B+4.8%
FY2024Dec 31, 2024$13.58B+24.2%
FY2023Dec 31, 2023$10.94B+12.0%
FY2022Dec 31, 2022$9.76B+0.3%
FY2021Dec 31, 2021$9.74B+62.5%
FY2020Dec 31, 2020$5.99B-1.1%
FY2019Dec 31, 2019$6.06B+2.1%
FY2018Dec 31, 2018$5.93B+3.0%
FY2017Dec 31, 2017$5.76B-2.3%
FY2016Dec 31, 2016$5.89B-1.8%
FY2015Dec 31, 2015$6.00B–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.05B+59.2%
Q2 FY2025Jun 30, 2025$3.55B+94.0%
Q2 FY2024Jun 30, 2024$3.01B+116.6%
Q2 FY2023Jun 30, 2023$2.67B+96.7%
Q2 FY2022Jun 30, 2022$2.55B+86.9%
Q2 FY2021Jun 30, 2021$1.83B+35.6%
Q2 FY2020Jun 30, 2020$1.39B–
Q2 FY2019Jun 30, 2019$1.36B–
Q2 FY2018Jun 30, 2018$1.36B–
Q2 FY2017Jun 30, 2017$1.35B–

More AstraZeneca figures

See a number that looks wrong?